NCT02124148View on ClinicalTrials.gov

A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

167

Participants

Timeline

Start Date

June 18, 2014

Primary Completion Date

February 13, 2020

Study Completion Date

February 13, 2020

Conditions
Neoplasm MetastasisColorectal NeoplasmsBreast Cancer
Interventions
DRUG

Prexasertib

Administered IV

DRUG

Cisplatin

Administered IV

DRUG

Cetuximab

Administered IV

DRUG

G-CSF

Administered SC

DRUG

Pemetrexed

Administered IV

DRUG

Fluorouracil

Administered IV

DRUG

LY3023414

Administered PO

DRUG

Leucovorin

Administered IV

Trial Locations (5)

34232

Florida Cancer Specialists, Sarasota

37203

Sarah Cannon Research Institute SCRI, Nashville

Tennessee Oncology PLLC, Nashville

73104

University of Oklahoma Health Sciences Center, Oklahoma City

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT02124148 - A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer | Biotech Hunter | Biotech Hunter